Biotech 2050 Podcast
Personalized regenerative medicines, Nabiha Saklayen, PhD, Co-Founder & CEO, Cellino
about a year ago
Engaging the immune system against disease, Andrew Allen, Co-Founder, President & CEO, Gritstone bio
about a year ago
Novel approach to targeted protein degradation, Nicki Thompson, CEO, Amphista Therapeutics
about a year ago
Envisioning people focused clinical trials, Michael Rosenblatt, VP of Clinical Operations, Roche
about a year ago
Power of RNA to restore healthy gene expression, Josh Mandel-Brehm, President & CEO, CAMP4 Tx
about a year ago
JPM23 Special: Rare diseases, Eslie Dennis, Kyowa Kirin, Arthur Suckow, DTx, & James Mackay, Aristea
about a year ago
JPM23 Special: Redefining cystic fibrosis treatment, Mike Cloonan, Pres. & CEO, Sionna Tx
about a year ago
JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics
about a year ago